1
|
Maligres PE, Peng F, Calabria R, Campeau LC, Chen W, Dormer PG, Green M, He CQ, Hyde AM, Klapars A, Larsen MU, Limanto J, Liu G, Liu Y, Moment A, Nowak T, Ruck RT, Shevlin M, Song ZJ, Tan L, Tong W, Waldman JH, Ye H, Zhao R, Zhou G, Zompa MA, Zultanski SL. Manufacturing Process Development for Uprifosbuvir (MK-3682): A Green and Sustainable Process for Preparing Penultimate 2′-Deoxy-α-2′-Chloro-β-2′-Methyluridine. Org Process Res Dev 2022. [DOI: 10.1021/acs.oprd.2c00191] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
Affiliation(s)
- Peter E. Maligres
- Process Research and Development, Merck & Co., Inc., Rahway, New Jersey 07065, United States
| | - Feng Peng
- Process Research and Development, Merck & Co., Inc., Rahway, New Jersey 07065, United States
| | - Ralph Calabria
- Process Research and Development, Merck & Co., Inc., Rahway, New Jersey 07065, United States
| | - Louis-Charles Campeau
- Process Research and Development, Merck & Co., Inc., Rahway, New Jersey 07065, United States
| | - Wenyong Chen
- Process Research and Development, Merck & Co., Inc., Rahway, New Jersey 07065, United States
| | - Peter G. Dormer
- Process Research and Development, Merck & Co., Inc., Rahway, New Jersey 07065, United States
| | - Meredith Green
- Process Research and Development, Merck & Co., Inc., Rahway, New Jersey 07065, United States
| | - Cyndi Qixin He
- Process Research and Development, Merck & Co., Inc., Rahway, New Jersey 07065, United States
| | - Alan M. Hyde
- Process Research and Development, Merck & Co., Inc., Rahway, New Jersey 07065, United States
| | - Artis Klapars
- Process Research and Development, Merck & Co., Inc., Rahway, New Jersey 07065, United States
| | - Mona Utne Larsen
- Process Research and Development, Merck & Co., Inc., Rahway, New Jersey 07065, United States
| | - John Limanto
- Process Research and Development, Merck & Co., Inc., Rahway, New Jersey 07065, United States
| | - Guiquan Liu
- Shanghai SynTheAll Pharmaceutical Co. Ltd., 9 Yuegong Road, Jinshan District, Shanghai 201507, China
| | - Yizhou Liu
- Process Research and Development, Merck & Co., Inc., Rahway, New Jersey 07065, United States
| | - Aaron Moment
- Process Research and Development, Merck & Co., Inc., Rahway, New Jersey 07065, United States
| | - Timothy Nowak
- Process Research and Development, Merck & Co., Inc., Rahway, New Jersey 07065, United States
| | - Rebecca T. Ruck
- Process Research and Development, Merck & Co., Inc., Rahway, New Jersey 07065, United States
| | - Michael Shevlin
- Process Research and Development, Merck & Co., Inc., Rahway, New Jersey 07065, United States
| | - Zhiguo Jake Song
- Process Research and Development, Merck & Co., Inc., Rahway, New Jersey 07065, United States
| | - Lushi Tan
- Process Research and Development, Merck & Co., Inc., Rahway, New Jersey 07065, United States
| | - Weidong Tong
- Process Research and Development, Merck & Co., Inc., Rahway, New Jersey 07065, United States
| | - Jacob H. Waldman
- Process Research and Development, Merck & Co., Inc., Rahway, New Jersey 07065, United States
| | - Honglin Ye
- Shanghai SynTheAll Pharmaceutical Co. Ltd., 9 Yuegong Road, Jinshan District, Shanghai 201507, China
| | - Ralph Zhao
- Process Research and Development, Merck & Co., Inc., Rahway, New Jersey 07065, United States
| | - George Zhou
- Process Research and Development, Merck & Co., Inc., Rahway, New Jersey 07065, United States
| | - Michael A. Zompa
- Process Research and Development, Merck & Co., Inc., Rahway, New Jersey 07065, United States
| | - Susan L. Zultanski
- Process Research and Development, Merck & Co., Inc., Rahway, New Jersey 07065, United States
| |
Collapse
|
2
|
Müggenburg F, Müller S. Azide-modified Nucleosides as Versatile Tools for Bioorthogonal Labeling and Functionalization. CHEM REC 2022; 22:e202100322. [PMID: 35189013 DOI: 10.1002/tcr.202100322] [Citation(s) in RCA: 12] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/13/2021] [Revised: 02/10/2022] [Accepted: 02/10/2022] [Indexed: 02/06/2023]
Abstract
Azide-modified nucleosides are important building blocks for RNA and DNA functionalization by click chemistry based on azide-alkyne cycloaddition. This has put demand on synthetic chemistry to develop approaches for the preparation of azide-modified nucleoside derivatives. We review here the available methods for the synthesis of various nucleosides decorated with azido groups at the sugar residue or nucleobase, their incorporation into oligonucleotides and cellular RNAs, and their application in azide-alkyne cycloadditions for labelling and functionalization.
Collapse
Affiliation(s)
- Frederik Müggenburg
- Institut für Biochemie, Universität Greifswald, Felix-Hausdorff-Straße 4, 17487, Greifswald, Germany
| | - Sabine Müller
- Institut für Biochemie, Universität Greifswald, Felix-Hausdorff-Straße 4, 17487, Greifswald, Germany
| |
Collapse
|
4
|
Bookser BC, Raffaele NB, Reddy KR, Fan K, Huang W, Erion MD. Synthesis of 3'-amino-3'-deoxyguanosine and 3'-amino-3'-deoxyxyloguanosine monophosphate HepDirect prodrugs from guanosine. NUCLEOSIDES NUCLEOTIDES & NUCLEIC ACIDS 2010; 28:969-86. [PMID: 20183565 DOI: 10.1080/15257770903307151] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 01/27/2023]
Abstract
The synthesis of 3'-amino-3'-deoxyguanosine and 3'-amino-3'-deoxyxyloguanosine monophosphate HepDirect prodrugs from guanosine is reported. Initial incorporation of N,N-dibenzylformamidino protection of the C2-amino of guanosine masked the reactivity of that group and simplified purification of subsequent analogues. The first key intermediate, 9-(2,5-bis-O-tert-butyldimethylsilyl-beta-D-ribofuranosyl)-2-N-(N,N-dibenzylformamidino)guanine (3a), was prepared in 60% yield after recycling of the undesired 3',5'-bis-O-protected byproduct (4a) by simple equilibration in methanol to a mixture of the two bis-O-protected compounds. Thus, protected, the 3'-position was manipulated to form the 3'-deoxyribo- or 3'-deoxyxylo-3'-azido derivatives (9 or 16, respectively). Further selective manipulations provided the cis-5'-monophosphate (3-chlorophenyl)-1,3-propanyl diester prodrugs (HepDirect prodrugs), 15 and 21. These HepDirect prodrugs were demonstrated to activate to their respective NTPs in rat hepatocytes.
Collapse
|